DE602004014135D1 - Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität - Google Patents

Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität

Info

Publication number
DE602004014135D1
DE602004014135D1 DE602004014135T DE602004014135T DE602004014135D1 DE 602004014135 D1 DE602004014135 D1 DE 602004014135D1 DE 602004014135 T DE602004014135 T DE 602004014135T DE 602004014135 T DE602004014135 T DE 602004014135T DE 602004014135 D1 DE602004014135 D1 DE 602004014135D1
Authority
DE
Germany
Prior art keywords
compositions
irinotecantoxicity
predicting
ironotecan
genotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004014135T
Other languages
German (de)
English (en)
Inventor
Mark J Ratain
Federico Innocenti
Rienzo Anna Di
Carrie Grimsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of DE602004014135D1 publication Critical patent/DE602004014135D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE602004014135T 2003-05-30 2004-05-28 Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität Expired - Fee Related DE602004014135D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47482603P 2003-05-30 2003-05-30
PCT/US2004/016920 WO2004108954A1 (en) 2003-05-30 2004-05-28 Methods and compositions for predicting irinotecan toxicity

Publications (1)

Publication Number Publication Date
DE602004014135D1 true DE602004014135D1 (de) 2008-07-10

Family

ID=33511633

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014135T Expired - Fee Related DE602004014135D1 (de) 2003-05-30 2004-05-28 Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität

Country Status (8)

Country Link
US (1) US7807350B2 (enExample)
EP (1) EP1629111B1 (enExample)
JP (1) JP2006526412A (enExample)
AT (1) ATE397091T1 (enExample)
CA (1) CA2527320A1 (enExample)
DE (1) DE602004014135D1 (enExample)
ES (1) ES2308208T3 (enExample)
WO (1) WO2004108954A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055261A1 (ja) * 2005-11-10 2007-05-18 The New Industry Research Organization Ｕｇｔ１ａ１遺伝子多型の検査法
KR101153058B1 (ko) 2006-11-30 2012-06-04 아크레이 가부시키가이샤 Ｕｇｔ1ａ1 유전자 증폭용 프라이머 셋트, 그것을 포함하는 ｕｇｔ1ａ1 유전자 증폭용 시약 및 그 용도
CN107858429A (zh) * 2017-11-10 2018-03-30 广州金域医学检验集团股份有限公司 用于检测ugt1a1基因启动子区ta重复多态性的扩增引物、方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
DE69734237T2 (de) 1996-03-01 2006-07-06 The University Court Of The University Of Dundee, Dundee Versuchsystem für einen Arzneimittelversuch
US6287834B1 (en) * 1996-05-17 2001-09-11 Endorecherche, Inc. Characterization and use of an isolated uridine diphospho-glucuronosyltransferase
DE19744676A1 (de) 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Kombinationspräparate für die Therapie von Tumoren
WO1999057322A2 (en) 1998-05-07 1999-11-11 Axys Pharmaceuticals, Inc. Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
US6448003B1 (en) * 1998-06-10 2002-09-10 Dna Sciences Laboratories, Inc. Genotyping the human phenol sulfotransferbase 2 gene STP2
US6407117B1 (en) * 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US6319678B1 (en) * 1998-06-26 2001-11-20 Panvera Corporation Process for glucuronidation screening
US6586175B1 (en) * 1998-07-28 2003-07-01 Dna Sciences Laboratories, Inc. Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
AU2001255397A1 (en) 2000-04-18 2001-10-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
EP1325152A2 (en) 2000-07-14 2003-07-09 F. Hoffmann-La Roche Ag Method for detecting pre-disposition to hepatotoxicity
AU2002245039A1 (en) 2000-11-28 2002-07-30 Dna Sciences Laboratories, Inc. Genetic typing of human genes and related materials and methods
EP1352970B1 (en) 2000-12-12 2010-06-02 Nagoya Industrial Science Research Institute Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabloized per se by ugt1a1 or whose intermediate is metabolized by the enzyme
DE10100238A1 (de) * 2001-01-05 2002-08-22 Hannover Med Hochschule Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests
WO2002059375A2 (en) * 2001-01-26 2002-08-01 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
WO2003013534A2 (en) 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Methods for the treatment of cancer with irinotecan based on cyp3a5
JP4096037B2 (ja) 2002-08-12 2008-06-04 国立大学法人滋賀医科大学 グルクロン酸転移酵素遺伝子の変異解析による薬剤代謝活性の予測方法
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan

Also Published As

Publication number Publication date
EP1629111A1 (en) 2006-03-01
CA2527320A1 (en) 2004-12-16
JP2006526412A (ja) 2006-11-24
ES2308208T3 (es) 2008-12-01
EP1629111B1 (en) 2008-05-28
WO2004108954A1 (en) 2004-12-16
ATE397091T1 (de) 2008-06-15
US20070197574A1 (en) 2007-08-23
US7807350B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
ATE536371T1 (de) Verfahren und zusammensetzungen zur gendeaktivierung
DE602004019812D1 (de) Marker für neuromyelitis optica
EP1246114A3 (en) Methods for genomic analysis
AU3084802A (en) Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
ATE480543T1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
WO2004101806A3 (en) Allele-specific expression patterns
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
MX2007016136A (es) Metodo para diagnosticar la enfermedad de alzheimer.
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
EP2249155A3 (en) Cancer markers
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
ATE544073T1 (de) Verfahren zur messung immunsuppressiver tacrolimus-, sirolimus- und cyclosporin-a- komplexe in einer blutprobe
DE602004014135D1 (de) Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität
WO2005080594A3 (en) Method for determining the risk of developing a neurological disease
ATE451476T1 (de) Zusammensetzungen und methoden zur bestimmung des mikrosatelliten instabilitäts (msi) status
DE602006013109D1 (de) Markerprotein zur verwendung bei der diagnose von bauchspeicheldrüsenkrebs
DE602004031533D1 (de) Verbessertes verfahren zur atp-amplifikation und verwendung davon
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
ATE515576T1 (de) Protein c polymorphismen
ATE544852T1 (de) Verfahren zur beurteilung der gefahr arzneimittelinduzierter granulozytopenie
WO2005052180A3 (en) Ntrk1 genetic markers associated with progression of alzheimer’s disease
DE602005017925D1 (de) Verfahren zur abschätzung der sekundären verarbeitungseigenschaften von weizen auf der anzuchtstufe
ATE490344T1 (de) Abcbi-genotypisierung zur vorhersage der mikrotubuli-stabilisatorwirkstoffinduzierten toxizität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee